Pauwels R A, Löfdahl C G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J, Ullman A
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
N Engl J Med. 1997 Nov 13;337(20):1405-11. doi: 10.1056/NEJM199711133372001.
The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide.
After a four-week run-in period of treatment with budesonide (800 microg twice daily), 852 patients being treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 microg of budesonide plus placebo, 100 microg of budesonide plus 12 microg of formoterol, 400 microg of budesonide plus placebo, or 400 microg of budesonide plus 12 microg of formoterol. Terbutaline was permitted as needed. Treatment continued for one year; we compared the frequency of exacerbations of asthma, symptoms, and lung function in the four groups. A severe exacerbation was defined by the need for oral glucocorticoids or a decrease in the peak flow to more than 30 percent below the base-line value on two consecutive days.
The rates of severe and mild exacerbations were reduced by 26 percent and 40 percent, respectively, when formoterol was added to the lower dose of budesonide. The higher dose of budesonide alone reduced the rates of severe and mild exacerbations by 49 percent and 37 percent, respectively. Patients treated with formoterol and the higher dose of budesonide had the greatest reductions -- 63 percent and 62 percent, respectively. Symptoms of asthma and lung function improved with both formoterol and the higher dose of budesonide, but the improvements with formoterol were greater.
In patients who have persistent symptoms of asthma despite treatment with inhaled glucocorticoids, the addition of formoterol to budesonide therapy or the use of a higher dose of budesonide may be beneficial. The addition of formoterol to budesonide therapy improves symptoms and lung function without lessening the control of asthma.
长效吸入型β2受体激动剂在治疗哮喘中的作用尚不确定。在一项双盲研究中,我们评估了在低剂量和高剂量吸入糖皮质激素布地奈德中添加吸入福莫特罗的效果。
在接受布地奈德(每日两次,每次800微克)为期四周的导入期治疗后,852名接受糖皮质激素治疗的患者被随机分配至通过干粉吸入器(都保)每日两次给予的四种治疗之一:100微克布地奈德加安慰剂、100微克布地奈德加12微克福莫特罗、400微克布地奈德加安慰剂或400微克布地奈德加12微克福莫特罗。必要时可使用特布他林。治疗持续一年;我们比较了四组中哮喘加重的频率、症状和肺功能。严重加重定义为需要口服糖皮质激素或连续两天峰值流速降至基线值以下30%以上。
在低剂量布地奈德中添加福莫特罗时,严重和轻度加重的发生率分别降低了26%和40%。单独使用高剂量布地奈德时,严重和轻度加重的发生率分别降低了49%和37%。接受福莫特罗和高剂量布地奈德治疗的患者降低幅度最大,分别为63%和62%。福莫特罗和高剂量布地奈德均可改善哮喘症状和肺功能,但福莫特罗的改善效果更佳。
对于尽管接受吸入糖皮质激素治疗仍有持续性哮喘症状的患者,在布地奈德治疗中添加福莫特罗或使用更高剂量的布地奈德可能有益。在布地奈德治疗中添加福莫特罗可改善症状和肺功能,且不降低哮喘控制水平。